• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Solana Company filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Regulation FD Disclosure

    4/27/26 8:43:12 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email
    false 0001610853 0001610853 2026-04-27 2026-04-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      

    Date of Report (Date of earliest event reported): April 27, 2026

     

     

     

    SOLANA COMPANY

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38445   36-4787690

    (State or other jurisdiction

      (Commission File Number) 

    (IRS Employer

    of incorporation)     Identification No.)

     

    642 Newtown Yardley Road, Suite 100

    Newtown, PA

      18940
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (215) 944-6100

     

    N/A 

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange on which registered
    Class A Common Stock, $0.001 par value   HSDT   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 3.02Unregistered Sales of Equity Securities.

     

    Reference is made to the disclosure under Item 8.01 below which is hereby incorporated in this Item 3.02 by reference.

     

    The Put Options (as defined below) have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder.

     

    Item 7.01 Regulation FD Disclosure.

     

    On April 27, 2026 the Company issued a press release announcing the terms of the Registered Direct Offering (as defined below), a copy of which is furnished as Exhibit 99.1 hereto.

     

    The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

     

    Item 8.01 Other Events.

     

    Registered Direct Offering

     

    On April 27, 2026, Solana Company (the “Company”) entered into securities purchase agreements (collectively, the “RDO Purchase Agreements”) with the purchasers named therein (the “Purchasers”), pursuant to which (i) the Company issued and sold to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 3,076,922 shares (the “Shares”) of the Company’s Class A common stock, $0.001 par value per share (the “Common Stock”). The offering price of each Share was $2.60 per share (the “Offering Price”). The net proceeds to the Company from the Registered Direct Offering are expected to be approximately $7.9 million.

     

    The Company currently plans to use the net proceeds from the Registered Direct Offering for accumulating SOL, working capital and general corporate purposes, business expansion and other strategic initiatives.

     

    The RDO Purchase Agreements contain customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, including for liabilities arising under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the RDO Purchase Agreements were made only for the purposes of such agreement and as of the specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.

     

    The Registered Direct Offering was made pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-290429), as amended, that became effective on April 8, 2026, and a related base prospectus and prospectus supplement (the “Prospectus Supplement”) thereunder.

     

    The foregoing description of the RDO Purchase Agreements does not purport to be complete and is qualified in its entirety by the full text of the form of RDO Purchase Agreement, a copy of which is attached hereto as Exhibit 4.1 and incorporated by reference herein.

     

     

     

     

    Put Option Agreement

     

    In connection with the Registered Direct Offering, the Company entered into put option agreements (collectively, the “Put Option Agreements”) with the Purchasers pursuant to which the Company granted each Purchaser the right to require the Company to repurchase all or a portion of the shares of Common Stock it purchased in the Registered Direct Offering at a price per share equal to the Offering Price plus an amount that would result in an internal rate of return of 7.0% per annum (collectively, the “Put Options”). The Put Options may be exercised in connection with the occurrence of certain qualifying events, including the 12-month and 18-month anniversaries of the closing of the Registered Direct Offering, a failure of the Company’s net debt to total capitalization ratio to remain at or below 30%, or a suspension or halt of trading in the Common Stock on the applicable trading market exceeding a specified number of consecutive trading days or the issuance of a delisting notice.

     

    The foregoing description of the terms and conditions of the Put Options does not purport to be complete and is qualified in its entirety by the full text of the form of Put Option Agreement, a copy of which is attached hereto as Exhibit 4.2, and incorporated by reference herein.

     

    In connection with the filing of the prospectus supplement for the Registered Direct Offering, the Company is filing a legal opinion of its counsel, Cooley LLP, regarding the validity of the Shares being issued in the Registered Direct Offering, a copy of which is attached as Exhibit 5.1 to this Current Report.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit No.  Description
    4.1  Form of Securities Purchase Agreement, by and among Solana Company and the Purchasers, dated April 27, 2026.
    4.2  Form of Put Option Agreement, by and among Solana Company and the Purchasers, dated April 27, 2026.
    5.1  Opinion of Cooley LLP.
    23.1  Consent of Cooley LLP (Included in Exhibit 5.1).
    99.1  Press Release of Solana Company dated April 27, 2026.
    104  Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    Note Regarding Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements, including, without limitation, statements relating to the Company’s expectations regarding the the proceeds that the Company expects to receive from the Registered Direct Offering and the intended use of proceeds from the Registered Direct Offering. Forward-looking statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements speak only as of the date they are made and, except for the Company’s ongoing obligations under the U.S. federal securities laws, the Company undertakes no obligation to update any forward-looking statement.

     

    Forward-looking statements are subject to known and unknown risks and uncertainties and are based on estimates and assumptions that are subject to change or revision. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including, without limitation, market conditions as well as risks and uncertainties inherent in the Company’s business. For a discussion of these and other factors, please refer to the risk factors included in the Company’s Annual Report on Form 10-K, and the Company’s Quarterly Reports on Form 10-Q and other periodic reports filed from time to time with the SEC.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    SOLANA COMPANY.
         
    Dated: April 27, 2026 By: /s/ Jeffrey S. Mathiesen
      Jeffrey S. Mathiesen
     

    Chief Financial Officer, Treasurer and Secretary

     

     

     

    Get the next $HSDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    4/23/2026$3.00Buy
    B. Riley Securities
    4/6/2026$4.00Buy
    Maxim Group
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solana Company Reports First Quarter 2026 Financial Results

    NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent Business Updates Generated $3.6 million in revenue in the first quarter of 2026, with the increase primarily driven by the Company's SOL earning staking yieldExecuted approximately $3.5 million in share repurchases during the quarter under the Company's repurchase programAdvanced the Pacific Backbone validator infrastructure initiative through strategic partnership with Jito to accelerate staking infrastructure development and MEV capture capabilitiesContinued collaboration wit

    5/15/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026

    NEWTOWN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced that the Company will release its first quarter operating results on Friday, May 15 2026, after market close. Management will host a conference call to discuss the results and provide a business update as follows: Date:Friday, May 15, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived under the News & Events section of the Company's investor relations website.  About Solana Company Solana Company (NASDAQ:HSDT) is a listed digital a

    5/11/26 4:16:12 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific Region

    MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- Jito Foundation, the organization supporting the development of the Jito ecosystem and the team behind the execution infrastructure underpinning the Solana network, today announced a strategic partnership with Solana Company (NASDAQ:HSDT), a leading institutional blockchain infrastructure company for the Solana ecosystem. The partnership is intended to focus on building institutional-grade validator infrastructure, advancing yield optimization, and accelerating institutional adoption of Solana across the APAC region.  Bringing Solana's market layer infrastructure into APAC's financial hubsThrough the collaboration, Solana Company and the Jito Founda

    5/6/26 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jiang Cosmo Yi exercised 1,005,040 shares at a strike of $0.00 and covered exercise/tax liability with 610 shares (SEC Form 4)

    4 - Solana Co (0001610853) (Issuer)

    6/4/26 8:12:15 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Jiang Cosmo Yi

    4 - Solana Co (0001610853) (Issuer)

    6/4/26 8:10:56 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Straw Edward M was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)

    4 - Solana Co (0001610853) (Issuer)

    5/26/26 7:30:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    SEC Filings

    View All

    Solana Company filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Solana Co (0001610853) (Filer)

    5/29/26 5:16:57 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Solana Company

    424B5 - Solana Co (0001610853) (Filer)

    5/29/26 5:08:05 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SD filed by Solana Company

    SD - Solana Co (0001610853) (Filer)

    5/29/26 4:05:58 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Solana Company with a new price target

    B. Riley Securities initiated coverage of Solana Company with a rating of Buy and set a new price target of $3.00

    4/23/26 8:09:25 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Maxim Group resumed coverage on Solana Company with a new price target

    Maxim Group resumed coverage of Solana Company with a rating of Buy and set a new price target of $4.00

    4/6/26 8:28:30 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Tech downgraded by Noble Capital Markets

    Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

    11/15/21 10:55:44 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

    4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    2/15/24 4:06:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/15/23 7:00:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/4/23 8:30:12 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    View All

    Solana Company (NASDAQ: HSDT) Appoints Madelene Gani as Chief Operating Officer and Deputy CFO to Lead Next Phase of Growth

    Gani is a proven transformation leader with track record at Hedera Hashgraph, Aptos, Gemini Space Station, and JUUL Labs. She joins to accelerate Solana Company's next phase of growth.Gani brings deep financial and operational expertise in public companies, global financial infrastructure buildout, and operational scaling that has driven hundreds of millions in value creation across hyper-growth companies.Strategic hire signals Solana Company's commitment to institutional-grade operations as it expands its digital asset treasury and infrastructure globally. NEWTOWN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) today announced the appointment of Madelene Gani, CPA,

    4/9/26 4:15:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

    -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

    6/11/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    5/14/24 4:15:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    2/13/24 7:09:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Financials

    Live finance-specific insights

    View All

    Solana Company Reports First Quarter 2026 Financial Results

    NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent Business Updates Generated $3.6 million in revenue in the first quarter of 2026, with the increase primarily driven by the Company's SOL earning staking yieldExecuted approximately $3.5 million in share repurchases during the quarter under the Company's repurchase programAdvanced the Pacific Backbone validator infrastructure initiative through strategic partnership with Jito to accelerate staking infrastructure development and MEV capture capabilitiesContinued collaboration wit

    5/15/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026

    NEWTOWN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced that the Company will release its first quarter operating results on Friday, May 15 2026, after market close. Management will host a conference call to discuss the results and provide a business update as follows: Date:Friday, May 15, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived under the News & Events section of the Company's investor relations website.  About Solana Company Solana Company (NASDAQ:HSDT) is a listed digital a

    5/11/26 4:16:12 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care